AZN: H1 2020 results30 Jul 2020 08:51
AstraZeneca reported a 12% rise in total revenue in the first half of the year to USD12.63 billion, while core earnings per share rose 24% to USD2.01. The pharmaceutical firm said its 2020 full-year guidance was unchanged at high single-digit to low double-digit percentage growth in revenue and mid- to high-teens growth in core EPS.
Astra held its first interim dividend steady at USD0.90 per share.
It promised a "broad and equitable" supply of any Covid-19 vaccine that it develops during the pandemic at no profit.